Oct-Dec Earnings
Dr Reddy's Q3 consol net profit falls over 14% YoY, revenue rises 4.4%
This story was originally published at 17:16 IST on 21 January 2026
Register to read our real-time news.Informist, Wednesday, Jan. 21, 2026
MUMBAI – Dr. Reddy's Laboratories Ltd.'s consolidated net profit for the quarter ended December was INR 12.10 billion, down more than 14% from INR 14.14 billion a year ago but higher than analysts' estimate of INR 11.23 billion. The company's consolidated revenue for the quarter was INR 87.53 billion, up 4.4% from INR 83.81 billion a year ago.
* Dr Reddy's Oct-Dec consol net profit INR 12.10 bln vs INR 14.14 bln yr ago
* Analysts saw Dr Reddy's Oct-Dec consol net profit at INR 11.23 bln
* Dr Reddy's Oct-Dec consol revenue INR 87.53 bln vs INR 83.81 bln year ago
* Analysts saw Dr Reddy's Oct-Dec consol revenue at INR 83.45 bln
* Dr Reddy's Oct-Dec consol EBITDA INR 20.49 bln vs INR 22.98 bln year ago
* Dr Reddy's Oct-Dec consol EBITDA margin 23.5% vs 27.5% year ago
* Dr Reddy's Oct-Dec consol gross profit margin at 53.6% vs 58.7% year ago
* Dr Reddy's Oct-Dec global generics sales INR 79.1 bln, up 7% on year
* Dr Reddy's Apr-Dec consol net profit INR 39.75 bln vs INR 40.62 bln yr ago
* Dr Reddy's Oct-Dec N America generics sales INR 29.6 bln, down 12% on year
* Dr Reddy's Oct-Dec Europe generics sales INR 14.5 bln, up 20% on year
* Dr Reddy's Apr-Dec consol revenue INR 261.54 bln vs INR 241.16 bln year ago
More to follow
To read more please subscribe
Share this Story:
